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Vitamin D system is a complex pathway that includes precursors, active metabolites,
enzymes, and receptors. This complex system actives several molecular pathways and
mediates a multitude of functions. In addition to the classical role in calcium and bone
homeostasis, vitaminD plays “non-calcemic” effects in host defense, inﬂammation, immu-
nity, and cancer processes as recognized in vitro and in vivo studies. The aim of this
review is to highlight the relationship between vitamin D and cancer, summarizing sev-
eral mechanisms proposed to explain the potential protective effect of vitamin D against
the development and progression of cancer. Vitamin D acts like a transcription factor that
inﬂuences central mechanisms of tumorigenesis: growth, cell differentiation, and apopto-
sis. In addition to cellular and molecular studies, epidemiological surveys have shown that
sunlight exposure and consequent increased circulating levels of vitamin D are associated
with reduced reduced occurrence and a reduced mortality in different histological types
of cancer. Another recent ﬁeld of interest concerns polymorphisms of vitamin D receptor
(VDR); in this context, preliminary data suggest that VDR polymorphisms more frequently
associated with tumorigenesis are Fok1, Bsm1,Taq1, Apa1, EcoRV, Cdx2; although further
studies are needed to clarify their role in the cancer. In this review, the relationship between
vitamin D and cancer is discussed.
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VITAMIN D PATHWAY
VITAMIN D SYNTHESIS
The vitamin D system includes a group of fat-soluble pro-
hormones and their respective metabolites. There are two main
forms of vitamin D in nature: vitamin D2 (ergocalciferol) photo-
chemically synthesized in plants, and vitamin D3 (cholecalciferol)
synthesized in the skin of animals and humans in response to
sunlight too, in particular to ultraviolet B radiations of appro-
priate wavelength: 270–300 nm. In most countries in Europe and
in the US the requirement of vitamin D is given by 90% of the
7-dehydrocholesterol cholesterol synthesis in the skin from solar
irradiation and only about 10% are taken up by the diet (Norman,
1998). The classical synthetic pathway involves 25- and 1-alpha-
hydroxylation of vitamin D2 and D3, in the liver and kidney,
respectively. First hydroxylation occurs within the liver and lead
to the formation of 25(OH)D or calcidiol; second hydroxylation
occurs within the kidneys and constitutes the most biologically
active hormonal form of vitamin D: 1,25(OH)2D, or calcitriol
(Figure 1). Vitamin D compounds are transported by a speciﬁc
binding protein, vitamin D binding protein (DBP). Vitamin D
activity is limited by catabolic processes, mediated primarily by
a 24-hydroxylase (CYP24A1) which transforms the calcitriol in
1,24,25(OH)3D, a compound with a substantially lower afﬁn-
ity for the vitamin D receptor (VDR); this catabolite is further
metabolized to products which are then excreted such as calcitroic
acid. Vitamin D metabolism is complex and tightly regulated.
Rate limiting steps in the metabolism of vitamin D compounds
are the activity of CYP2R1 which is induced by low 25(OH)D
levels and the activity of CYP24A1 which is induced by 25(OH)D
and 1,25(OH)2D (Tuohimaa, 2008). While vitamin D metaboliz-
ing enzymes are located primarily in liver (CYP2R1) and kidney
(CYP27B1 and CYP24), catabolic enzymes are found in several
tissues. It has been demonstrated that potential vitamin D target
tissues (e.g., colon, prostate, breast, lung, pancreas) can synthe-
size and degrade calcitriol. Local production and degradation of
calcitriol have been suggested to represent a key factors in several
types of human cancer (Haussler et al., 1998; Schwartz et al., 2004;
Cross, 2007).
BIOLOGICAL ACTIVITY
The traditionally recognized role of vitamin D consist in the regu-
lation of bone metabolism and calcium-phosphorus homeostasis
but recently a lot of in vitro and in vivo studies recognized several
“non-calcemic” effects of vitamin D metabolites. Reduced levels
of vitamin D are linked with the onset and progression of various
diseases such as autoimmune diseases, respiratory infections, dia-
betes mellitus type 1 and type 2, hypertension and cardiovascular
disease, neuromuscular disorders, and cancer (Holick and Chen,
2008). Higher vitamin D exposure is hypothesized to prevent sev-
eral cancers, possibly through genomic effects modulated by the
VDR, and non-genomic effects: autocrine/paracrine metabolism
of theVDR’s ligands. The 1,25(OH)2D is a well-known potent reg-
ulator of cell growth and differentiation, there is a recent evidence
of an effect on cell death, tumor invasion, and angiogenesis, which
makes it a candidate agent for cancer regulation. Calcitriol exerts
signiﬁcant antitumoral activity in vitro and in vivo in: murine
squamous cell carcinoma (SCC), rat metastatic prostatic ade-
nocarcinoma Dunning (MLL) model systems, human prostatic
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FIGURE 1 |Vitamin D synthesis. Main forms of vitamin D in nature
are: vitamin D2 (ergocalciferol) that is photochemically synthesized
in plants, and vitamin D3 (cholecalciferol) that is synthesized in the
skin of animals and humans in response to sunlight. The synthetic
pathway involves 25- and 1-alpha-hydroxylation of vitamin D2 and
D3, in the liver and kidney, respectively. First hydroxylation occurs
within the liver and lead to the formation of 25(OH)D or calcidiol;
second hydroxylation occurs within the kidneys and constitutes the
most biologically active hormonal form of vitamin D: 1,25(OH)2D, or
calcitriol.
adenocarcinoma (PC-3 and LNCaP), human breast, colon, and
pancreatic cancer, as well as in leukemia, myeloma, and lym-
phoma lines (Reichekl et al., 1989; Zhou et al., 1990; Uhmann
et al., 2011).
GENOMIC AND NON-GENOMIC ACTIONS
Vitamin D and its analogous exert their effects through both
genomic and non-genomic pathways. 1,25(OH)2D operates
through pharmacologically distinct nuclear receptor-mediated
and plasma membrane-initiated mechanisms. 1,25(OH)2D inter-
acts with theVDR localized in the cell nucleus to generate genomic
effects or in caveolae of the plasma membrane to generate non-
genomic effects (rapid responses, RR). VDR is an intracellular
nuclear receptor active in over 30 different human tissues, its
activation involves over 60 genes in different cell lines. VDR are
distributed in many organs and tissues as follows: Cardiovascular
system: cardiomyocytes, smooth muscle cells; Endocrine system:
thyroid C-cells, parathyroid glands, Langerhans islets; Epider-
mis: hair follicles, keratocytes; Gastrointestinal System: stomach,
esophagus, intestine, liver; Immune System: thymus, T and B lym-
phocytes, bone marrow; Renal system: ascending portion of Henle
loop, juxtaglomerular cells; Respiratory system: alveolar epithe-
lium; Osteomuscular system: osteoblasts, chondrocytes, striated
muscle; Reproductive system: testis, ovary, and uterus; Central
nervous system: neurons.
In particular, both benign and malignant proliferative cells
express the VDR. Calcitriol bound to VDR forms heterodimers
with the retinoid X receptor (RXR) and its ligand (9 cis-retinoic
acid) and these dimers occupy speciﬁc nucleotide sequences (vita-
min D response elements or VDREs). In conjunction with several
transcription factors, this complex lead to the transcription of
vitamin D responsive genes (Figure 2). Among the numerous
genes transcriptionally activated by calcitriol there are CYP24A1,
BGLAP (osteocalcin), and CDKN1A (encoding p21Waf1/Cip1),
the growth arrest and DNA-damage-inducible gene, GADD45
gene; while the parathyroid hormone (PTH) gene is repressed by
calcitriol (Evans, 1988; Deeb et al., 2007).
Non-genomic pathways may cooperate with the classical
genomic pathway (Figure 3).Non-genomic signaling is rapid,does
not depend on transcription and may indirectly affect transcrip-
tion via cross-talk with other signaling pathway. Some data suggest
that non-genomic effects begin at the plasma membrane and
involve a non-classical membrane receptor and a novel receptor
for 1,25(OH)2D called 1,25D3-MARRS (membrane-associated,
rapid response steroid-binding; Nemere et al., 2004; Norman,
2006). Non-genomic actions of calcitriol induce the rapid translo-
cation of calcium across intestinal mucosal membranes. Binding
of 1,25(OH)2D at plasma membrane may result in the activation
of one or more second messenger systems, including phospho-
lipase C (PKC), protein kinase C, G protein-coupled receptors,
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FIGURE 2 | Effects of vitamin D receptor (VDR) activation on
tumorigenesis. Calcitriol bound to VDR forms heterodimers with the
retinoid X receptor (RXR) and its ligand (9 cis-retinoic acid), these dimers
occupy speciﬁc nucleotide sequences: vitamin D response elements
(VDREs). In conjunction with several transcription factors, this complex lead
to the transcription of vitamin D responsive genes.
or phosphatidylinositol-3-kinase (PI3K). There are a number of
possible outcomes including opening of the voltage-gated cal-
cium or chloride channels or generation of the second messengers.
Some of these second messengers, particularly RAF/MAPK, may
modulate a cross-talk with the nucleus for gene expression regu-
lation: ERK can enhance transcriptional activity of the VDR and
non-genomic activation of PKC may stabilize VDR via phospho-
rylation (Wali et al., 1990; Hsieh et al., 1991; Morelli et al., 2001).
Cytoplasmic signaling pathways are increasingly being recognized
to regulate cell growth and differentiation as well as apopto-
sis. 1,25(OH) 2D and its analogous induce G0/G1 arrest and an
inhibitory effect on the G1/S checkpoint of the cell cycle by up-
regulating p27 and p21, the cyclin dependent kinase inhibitors
implicated in G1 arrest (Wang et al., 1996). Calcitriol promotes
cleavage of caspase 3, polyadenyl ribose 6 phosphate (PARP), and
the growth-promoting/prosurvival signaling molecule mitogen-
activated protein kinase (MEK) in a caspase-dependent manner.
Moreover, calcitriol signiﬁcantly up-regulates the pro-apoptotic
signaling molecule MEKK-1 and inhibits the phosphorylation and
expression of Akt, a kinase that regulates a key cell survival path-
way (Peehl et al., 1994; McGuire et al., 2001; Fleet, 2008). Indirect
mechanisms include up-regulation of transforming growth factor-
beta and down-regulation of the epidermal growth factor recep-
tor. 1,25(OH)2D may induce apoptosis either indirectly through
effects on the insulin-like growth receptor and tumor necrosis
factor-alpha or more directly via the Bcl-2 family system, the
ceramide pathway, the death receptors (e.g., Fas), and the stress-
activated protein kinase pathways (Jun N terminal kinase and
p38). The inhibition of tumor invasion and metastasis has been
demonstrated and mechanisms involved include inhibition of ser-
ine proteinases, metalloproteinases, and angiogenesis (Seubwai
FIGURE 3 | 1,25(OH)2D operates through nuclear receptor-mediated
and plasma membrane-initiated mechanisms. 1,25(OH)2D interacts
with the vitamin D receptor (VDR) localized in the cell nucleus to generate
genomic effects or in caveolae of the plasma membrane to generate
non-genomic effects (rapid responses, RR). Moreover, 1,25(OH)2D can
directly interact with a novel receptor for 1,25(OH)2D called
1,25D3-MARRS (membrane-associated, rapid response steroid-binding).
Binding of 1,25(OH)2D at plasma membrane may activate one or more
second messenger systems, including phospholipase C (PKC), protein
kinase C, G protein-coupled receptors, or phosphatidylinositol-3-kinase
(PI3K). Possible outcomes include opening of the voltage-gated calcium or
chloride channels or generation of second messengers. Some of these
second messengers, particularly RAF/MAPK, may modulate a cross-talk
with the nucleus for gene expression regulation.
et al., 2007). 1,25(OH)D inhibits the proliferation of endothelial
cells in vitro and reduces angiogenesis in vivo. However, calcitriol
was not able to induce apoptosis and cell cycle arrest in endothelial
cells isolated fromnormal tissues,while these effectswere observed
in tumor-derived endothelial cells (Trump et al., 2010). Endothe-
lial cell tube formation induced by vascular endothelial growth
factor (VEGF) and tumor growth are inhibited in vivo by cal-
citriol administration to mice with VEGF-overexpressing MCF-7
xenografts (Merke et al., 1989; Mantell et al., 2000; Bernardi et al.,
2002; Pendás-Franco et al., 2008; Chung et al., 2009). In squa-
mous carcinoma cells, calcitriol promote the angiogenic factor
interleukin-8 (IL-8) but in prostate cancer cells calcitriol inter-
rupts IL-8 signaling, inducing the inhibition of endothelial cell
migration and tube formation (Lin et al., 2002; Bao et al., 2006).
The inhibition of prostate and lung cancer metastasis is observed
in murine models treated with calcitriol: anti-angiogenic activity
of calcitriol may contribute to this effect (Getzenberg et al., 1997;
Nakagawa et al., 2005).
Vitamin D acts cooperatively with calcium serum levels, both
pathways converge in the inhibition of Wnt/beta-catenin with the
ﬁnal antiproliferative effect; high levels of serum calcium modu-
late themetabolismof extrarenal 1,25(OH)2D encouraging higher
local concentrations steady-state, 1,25(OH)2D also up-regulates
the expression of calcium-sensitive receptors by enhancing the
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antiproliferative response to high concentrations of extracellular
calcium (Holick and Chen, 2008; Peterlik et al., 2009).
Some recent data suggest that the form electively involved in
cellular processes of differentiation and mitosis (non-calcemic
effects), is represented by 25(OH)D (calcidiol), which occupies
a lot of VDR in vivo while 1,25(OH)2D (calcitriol) might be more
involved in calcium homeostasis (Tuohimaa, 2008).
ROLE OF VITAMIN D IN CANCER DEVELOPMENT
Several levels of evidence support the relationship between vit-
amin D and cancer: (1) low circulating levels of vitamin D are
associated with increased risk of developing cancer, (2) a high
intake of vitamin D is associated with a reduced risk of cancer,
(3) the aggressiveness of a cancer is lower in summer when the
production of vitamin D is higher, (4) polymorphisms of genes
encoding proteins involved in the signal pathway of vitamin D
affect the risk of developing cancer. This relationship is supported
by in vitro studies and epidemiologic studies. A lot of in vitro
studies have demonstrated that exposure of tumor cells to high
concentrations of vitaminDcompounds inhibit their proliferation
and induce differentiation. Numerous epidemiologic studies have
shown the association between factors expected to reduce vitamin
D levels (e.g., geography and latitude, history of sun exposure,
lifestyle) and the increased rates of cancer, highlighting the pro-
tective effects of sunlight and high levels of vitamin D on various
types of tumors (Ma et al., 1998; Janowsky et al., 1999; Feskanich
et al., 2004; Jacobs et al., 2004; Robsahm et al., 2004; Lowe et al.,
2005; Boscoe and Schymura, 2006; Ali and Vaidya, 2007). Apperly
in 1941 ﬁrstly suggested that the difference in cancer incidence
observed in North America at different latitudes (North-South
gradient: high in the north, low in the South), was correlated with
the cutaneous production of vitamin D in the areas with a major
sun exposure (Apperly, 1941; Garland and Garland, 1980). In 1981
it was shown that 1,25(OH)2D, in nanomolar concentrations, was
able to signiﬁcantly inhibit the proliferation of human melanoma
cells and stimulate differentiation of myeloid leukemia cells (Wali
et al., 1990; Hsieh et al., 1991; Morelli et al., 2001). Many stud-
ies have conﬁrmed an association between low serum levels of
vitamin D and incidence and mortality of several type of tumors
such as melanoma, breast cancer, prostate, colorectal, ovarian, kid-
ney, esophagus, stomach, non-Hodgkin’s lymphoma (Grant and
Garland, 2006; Pilz et al., 2008; Hutchinson et al., 2010; Grant
et al., 2011). However, data about vitamin D and cancer are often
conﬂicting, with a considerable variability.
CANCER, VITAMIN D, INFLAMMATION, AND IMMUNITY
Inﬂammation is implicated in the development and progression
of many cancer types. Recent data have emphasized the critical
role of immune and inﬂammatory processes in the carcinogen-
esis of the colon, liver, stomach, and prostate cells (Coussens
and Werb, 2002; Haverkamp et al., 2008). Although the inter-
action between vitamin D, inﬂammation, and cancer is not yet
clear, the observation that VDR is expressed signiﬁcantly in the
immune system has raised to the possibility that vitamin D and
its analogous may exert immunomodulatory activity (Lucia and
Torkko, 2004; Narayanan et al., 2006; Trump et al., 2006; Krishnan
et al., 2007). Cellular studies revealed that Vitamin D modulates
the activity of various defense and immune cells including blood
monocytes, macrophages, antigen-presenting cells and activated
CD4 T cells, or epithelial cells (Bhalla et al., 1983; Manolagas
et al., 1986; Veldman et al., 2000). It is well established that
1,25(OH)2D modulates T lymphocyte proliferation and function.
The biologically active 1,25(OH)2D inhibits proliferation of TH
lymphocytes and shifts the expression of cytokines from a TH1
based response toward a TH2 based proﬁle. Current data sug-
gest that 1,25-(OH)2D acts on the adaptive immune response
by modulating the functions of dendritic cells. In addition, den-
dritic cells and activated T lymphocytes showed the capacity to
synthesize 1,25(OH)2D from sunlight-derived precursors sug-
gesting an immune autocrine/paracrine activity (Sigmundsdot-
tir et al., 2007). Although vitamin D has no direct antimicro-
bial activity, there is evidence that calcitriol can modulate host
response while its deﬁciency increases susceptibility and severity
in Mycobacterium tuberculosis infection. Calcitriol in the pres-
ence of 25(OH)D raises antimicrobial activity of macrophages
against M. tuberculosis after stimulation with mycobacterial lig-
ands. Mycobacterial activation of toll-like receptor-2 (TLR-2)
raises the expression of both VDR and CYP27B that leads to
an increased conversion of 25(OH)D to 1,25(OH)2D and sub-
sequent expression of the antimicrobial peptide cathelicidin via
VDR (Garland et al., 2007; Colston, 2008). In addition, a recent
study has shown that a single high oral dose of vitamin D3
(100,000 IU) signiﬁcantly enhances the antimycobacterial immu-
nity of tuberculosis contacts by restricting recombinant M. bovis
in vitro (Martineau et al., 2007). Interestingly, these recent ﬁnd-
ings add credence to the historical tuberculosis treatment with
sunlight and cod liver oil, in fact, more than a century ago (1849),
the British physician C. J. B. Williams described a “marked and
unequivocal improvement” after treatment with cod liver oil (rich
in vitamin D) in the treatment of tuberculosis.
VDR POLYMORPHISMS
Results from previous studies on the association of VDR polymor-
phisms with different cancer types are somewhat contradictory,
and the role of VDR in the etiology of cancer is still equivo-
cal. Genetic studies have investigated the possible relationship
between some histotypes of cancer and the detection of speciﬁc
single-nucleotide polymorphisms (SNPs) of the VDR gene (VDR
SNPs) and other selected genes involved in the pathway of vit-
amin D such as protein gene transport of vitamin D, CYP27B1
and CYP24A1, which respectively encode the enzymes that syn-
thesizes and degrades 1,25(OH) 2D (McCullough et al., 2009).
Most studies are focused on polymorphisms of VDR, whose gene
is located on chromosome 12q12–q14 (Table 1). About 200 differ-
ent described SNPs VDR, VDR polymorphisms more frequently
associatedwith tumorigenesis are: Fok1,Bsm1,Taq1,Apa1,EcoRV,
Cdx2, although data in this area are often contradictory and yet to
be clariﬁed. Themost frequently studied SNPsVDRare the restric-
tion fragment length polymorphisms FokI and BsmI. The FokI
restriction fragment length polymorphism, located in the coding
region of the VDR gene, lead to the production of a VDR protein
that is three amino acids longer. Although no signiﬁcant differ-
ences in ligand afﬁnity, DNA binding, or transactivation activity
found between these two VDR forms, the shorter VDR variant
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Table 1 |VDR polymorphisms associated with cancer.
Cancer VDR polymorphisms
Prostate Fok I, BsmI, Taq, ApaI, poly (A)
Breast Fok I, BsmI,TaqI, ApaI, poly (A)
Melanoma Fok I, BsmI
Colorectal Fok I, BsmI
Thyroid ApaI, Fok I,TaqI
display higher potency than the longer one. The BsmI is intronic
and located at the 3-end of the gene. BsmI does not alter the
amount, structure, or function of the ﬁnalVDR protein produced,
but it is strongly linked with a poly (A) repeat and may affect
VDR messenger RNA stability. The strongest associations found
by a recent meta-analysis regard melanoma with BsmI and FokI;
prostate cancer with BsmI, FokI, ApaI; breast cancer with BsmI,
FokI, and TaqI (Chen et al., 2009; Kostner et al., 2009; Raimondi
et al., 2009). In particular, in prostate cancer, the haplotype analysis
showed that the allelic variants BsmI(B)–APAI(A)–TaqI (t ) were
associated with a higher Gleason score than allelic variants BsmI
(b)–APAI (a)–TaqI (T). For breast cancer Lowe et al. have shown
a risk of developing cancer six times higher for women with low
levels of 25(OH)D (<20 ng/ml) associated with the BsmI bb geno-
type than women with sufﬁcient levels of 25(OH)D (>20 ng/ml)
and BB or Bb genotype (Lowe et al., 2005; Chen et al., 2009). With
regard to melanoma, a meta-analysis acknowledged the strongest
association with the f allele of the polymorphism Fok1 and the
B allele of the polymorphism Bsm1 (Gandini et al., 2009). Stud-
ies of Fok1 polymorphisms in colorectal cancer have provided
strongly conﬂicting data although it seems that the genotype ff is
associated with a slightly lower risk of developing this cancer com-
paredwith FF genotype; but a recentmeta-analysis of all studies on
colorectal cancer andVDRSNPs support the evidence of an associ-
ation between BsmI polymorphism with a lower colorectal cancer
risk risk (RR= 0.57, 0.36–0.89 for BB versus bb, eight studies);
rather than FokI, PolyA, TaqI, Cdx2, and ApaI VDR polymor-
phisms (McCullough et al., 2009; Touvier et al., 2011). Regarding
differentiated thyroid cancer, a study conducted in 2009 on 172
patients found the association with VDR polymorphisms FokI,
TaqI, and ApaI, namely: while the alleles AA and FF of the ApaI
and FokI VDR polymorphisms and the haplotype tABF confer to
protection from follicular carcinoma, the haplotype Tabf appeared
tobe associatedwith an increased follicular thyroid carcinoma risk:
these ﬁndings need to be conﬁrmed in studies with larger numbers
of patients (Penna-Martinez et al., 2009). Furthermore, genotypes
and haplotypes so-called“at risk”are inﬂuenced by environmental
factors and lifestyle, such as calcium and vitamin D levels, but no
study clariﬁes these interactions.
EFFECTS OF CANCER ON VITAMIN D SYSTEM
The attention is mainly focused on the impact that vitamin D has
on cancer, but it is also important to understand the effects that
cancer has on vitamin D system. Up-regulation of VDR expression
has been shown in several tumors and is thought to represent an
important endogenous response to tumor progression. Matusiak
et al. (2005) showed that VDR levels were low in normal colonic
epithelial cells; were increased in aberrant crypt foci, polyps, and
well-differentiated tumor cells; and then declined as a function of
tumor cell de-differentiation; this suggests that the progression of
colon cancer can cause a reduced response to the action of vita-
min D, due to a reduced rate of this protein that translocates to the
nucleus as tumors progress. Over-expression of VDR indicates a
good prognosis for cholangiocarcinoma indicating an active role
for VDR in mediating the antiproliferative effects of 1,25(OH)2D
in cholangiocarcinoma cell lines. The over-expression of VDR
seems to be an endogenous mechanism of response to tumor
progression correlated with a better prognosis; through recep-
tor over-expression in tumor cell lines is in fact enhanced the
antiproliferative effect of vitamin D (Pelczynska et al., 2005; Seub-
wai et al., 2007). A reduced expression of the enzyme 25 (OH)
D-1α-hydroxylase in malignant cells has also suggested but it has
not been uniformly observed in all tumor types; Friedrich et al.
(2006) described a major expression of the enzyme 25 (OH) D-
1α-hydroxylase in breast cancer cells than in healthy breast cells.
Moreover, some tumor cell lines, such as breast and colorectal
cancer cells, showed an ampliﬁcation of the expression of the cata-
bolic enzyme 24-hydroxylase (Townsend et al., 2005; Beildeck and
Byers, 2009). All these ﬁndings reinforce the concept that higher
vitamin D levels represent a protective factor against the onset and
progression of cancer.
The main tumor models taken in consideration to investigate
the relationship between Vitamin D and cancer are prostate can-
cer, breast cancer,melanoma, colorectal cancer. Endocrine tumors
also represent an interestingmodel because speciﬁc hormonesmay
inﬂuence the Vitamin D pathway.
VITAMIN D AND PROSTATE CANCER
Studies investigating the role of vitamin D in prostate cancer have
rapidly developed since the assumption that the deﬁciency of vit-
amin D engrave on cancer risk up to the most recent clinical
trials involving the administration of vitamin D analogs for cancer
treatment (Woo et al., 2005; Petrioli et al., 2007; Schwartz, 2009).
Prostate cancer is the most common male cancer in the Western
world. Both healthy and tumor prostate cells, have receptors for
vitamin D and contain key enzymes for vitamin D metabolism.
Since 1990 it was observed that the major risk factors for prostate
cancer, such as advanced age, black race, residence in higher lat-
itudes, were all associated with reduced vitamin D synthesis and
inversely related to exposure to ultraviolet radiation (Schwartz
and Hulka, 1990). The antiproliferative, pro-differentiating, and
anti-metastatic effects of vitamin D metabolites on prostate cells
have been demonstrated in vitro but are not always as obvious
in vivo (Ahn et al., 2009; Gupta et al., 2009; Travis et al., 2009;
Barnett et al., 2010; Gilbert et al., 2011). The mechanisms of these
effects were not yet fully characterized but include inhibition of
cell proliferation (cell cycle arrest), invasion (inhibitionof metallo-
proteinases),migration,metastasis, angiogenesis (Schwartz,2009).
Limited data suggest that vitamin D alone has therapeutic value in
prostate cancer. In a pilot study,Woo et al. showed a prolongation
of PSA doubling time after cholecalciferol administration in men
who had a PSA relapse after deﬁnitive therapy. In an open-label,
non-randomized pilot study of calcitriol among men with early
recurrent prostate cancer, authors observed that calcitriol slowed
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the rate of PSA rise compared with the pre-treatment rate. Osborn
et al. reported a trial of calcitriol in patients with hormone refrac-
tory prostate cancer in which oral calcitriol was given daily. No
objective responses were noted in that study, and dose escalation
of oral 1,25(OH)2D was limited by hypercalcemia encountered in
30% of patients (Osborn et al., 1995; Gross et al., 1998; Woo et al.,
2005). After these initial studies several authors demonstrated that
intermittent, high-dose calcitriol regimens are safe and feasible
(Beer et al., 2001; Morris et al., 2004; Chen and Kittaka, 2011). A
shortcoming of all previous studies of vitamin D-based therapies
is that calcitriol and the other analogous that were studied were
used at doses well below the maximum tolerated dose (MTD).
In preclinical models, both in vitro and in vivo exposure to very
high concentrations of calcitriol are necessary to produce antitu-
mor effects. Muindi et al. (2002) demonstrated that the exposure
achieved in patients was only 20% to 33% of the exposure that was
identiﬁed as necessary to produce activity in preclinical models.
Chadha et al. showed that the highest dose of intermittent calcitriol
ever given in a phase 2 trial in any disease (iv calcitriol at a dose of
74μg weekly in combination with dexamethasone) was well toler-
ated but failed to produce a clinical or PSA response in men with
castration-resistant prostate cancer. Possible explanations include
calcitriol resistancemechanisms such as loss ofVDRand enhanced
calcitriol degradation by CYP24 (Chadha et al., 2010).
VITAMIN D AND BREAST CANCER
Breast cancer is one of the most common female cancers in the
Western population and there is a growing interest in identifying
the role and the relative importance of environmental risk factors,
lifestyle and diet in this type of tumor. The relationship between
vitamin D and breast cancer is supported by laboratoristic, epi-
demiological, and genetic studies (Garland et al., 2007;Abbas et al.,
2008; Colston, 2008; Mohr et al., 2008). Both healthy and cancer
breast cells express theVDRandgene ablation studies have showna
role ofVDR in physiologicalmammary gland development. Zinser
and Welsh (2004) recently showed that after the stimulation with
the carcinogen DMBA, mice knockout for VDR gene developed
a higher number of pre-malignant lesions compared to wild-type
mice. It is also very probable that breast cells are able to locally
synthesize 1,25(OH) 2D, since both healthy cells and cancer cells
express the 1α-hydroxylase enzyme activity. The antiproliferative
and pro-differentiating effects of vitamin D seems to regulate dif-
ferentiation in the breast by a balance between the activity of the
1α-hydroxylase and 24-hydroxylase enzymes, responsible respec-
tively for the synthesis and degradation of the active hormone
1,25(OH) 2D. Several studies have found an increased expression
of CYP24 in tumor cells compared to healthy cells, suggesting that
themalignant tissue present a tendency to thedegradationof active
vitamin D (Townsend et al., 2005). In conﬁrmation of this, several
meta-analysis found an inverse correlation between circulating
levels of 25(OH)D and risk of developing breast cancer, most pro-
nounced for values of 25(OH)D <20 ng/ml (Abbas et al., 2008).
Furthermore, an analysis of all studies focused on the relation-
ship between breast cancer and serum levels of 25(OH)D divided
into quintiles, showed among 1,760 subjects, a 50% reduced risk
of developing cancer with serum 25(OH)D>52 ng/ml, compared
to those with serum 25(OH)D <13 ng/ml. Levels of 25(OH)D
>52 ng/ml can be achieved by oral intake of 3,000 IU/day of vita-
min D analogs (equivalent to 2,000 IU/day orally in combination
with exposure to sunlight for about 12min/day; Garland et al.,
2007). A large study of 107 countries conﬁrmed a protective effect
of UV-B irradiation on the risk of developing breast cancer, regard-
less of overweight, age, alcohol consumption, and other covariates
(Mohr et al., 2008). There are few data regarding the relation
between vitamin D and recurrence of breast cancer after treat-
ment. Vrieling et al. investigated the survival in a large prospective
cohort of 1,295 postmenopausal breast cancer patients in relation
to post-diagnostic serum levels of 25(OH)D; the study showed that
lower serum calcidiol concentrations were associated with poorer
overall and distant disease-free survival. A previous study, the
Women’s Healthy Eating and Living (WHEL) Study, evaluated the
associations between circulating levels of 25(OH)D and dietary,
supplemental, and total intake of vitamin D and recurrent or
newbreast cancer events: no signiﬁcant associationswere observed
during pre and postmenopausal status for local, regional, or dis-
tant recurrence or death; although for premenopausal women was
observed a signiﬁcant inverse relation between dietary vitamin D
intake and recurrence (Jacobs et al., 2011; Vrieling et al., 2011).
VITAMIN D AND MELANOMA
In scientiﬁc and public communities, there is an ongoing dis-
cussion on the balance between positive and negative effects of
solar ultraviolet-exposure on skin cancers. The identiﬁcation of
an independent action of vitamin D on melanoma risk is difﬁ-
cult to establish given the contrasting and confounding effects of
solar exposure on skin melanocytes. Both UV-A and UV-B radi-
ation induce structural DNA-damage and is well established that
sunburns are crucial in the pathogenesis of SCC, basal cell car-
cinoma (BCC), and malignant melanoma (MM). It is accepted
that chronic sun exposure is the most important etiological fac-
tor for the development of non-melanoma skin cancer (NMSC)
through tissutal and genomic alterations, oxidative stress, and
pro-inﬂammatory actions (Egan, 2009). Data from UV-induced
carcinogenesis experiments in mice showed that the ﬁrst step
involves acquisition of UV-induced mutations in the p53 gene
by epidermal keratinocytes. On the other side, during the last
years, several evidences conﬁrmed that 1,25(OH)2D regulates
important cellular functions, including cellular growth and reg-
ulation of apoptosis in human keratinocytes, with antioxidative,
cytoprotective, and immunomodulatory effects in the skin, pro-
tecting human keratinocytes against UV-B induced cell damage.
It is well recognized that the photocarcinogenesis of skin cancer
is mainly due to mutations resulting from insufﬁcient repaired
DNA photoproducts. The most established DNA photoprod-
ucts caused by UV radiation are cyclobutane pyrimidine dimers
(CPDs). Recent investigations show that 1,25(OH)2D3 reduces
the number of CPDs in human keratinocytes after UV-B radi-
ation (Lee and Youn, 1998; De Haes et al., 2004; Trémezaygues
et al., 2006). Interestingly Lee et al. (2011) demonstrated that
calcitriol exert anticancer effects enhancing natural killer (NK)
cells susceptibility of human melanoma cells lines: 1,25(OH)2D-
resistant melanoma cells treated with 1,25(OH)2D showed higher
susceptibility to NK cells via heat shock protein 60 (Hsp60)-
mediated up-regulation of FAS expression. Melanoma cells, in
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addition to expressing theVDR,are able to synthesize 1,25(OH)2D
from 25(OH)D and proliferate much more slowly in the presence
of calcitriol. The expression of VDR and the growth inhibition
induced by 1,25(OH)2D have been noted in human MM cell
lines. It has also been demonstrated that calcitriol is able to pro-
mote apoptosis and to inhibit proliferation of human melanoma
cells in vitro (Evans et al., 1996; Seifert et al., 2004). In addition,
a recent study indicates a cross-talk between VDR and peroxi-
some proliferator-activated receptor (PPAR)-signaling pathways
through 1,25(OH)2D in melanoma cell lines. Since that bothVDR
and PPAR-signaling pathways regulate a lot of key genes for several
cellular functions including cell proliferation, cell differentiation,
immune responses, and apoptosis, the provided link betweenVDR
and PPAR may represent an important new tool for treatment and
prevention of melanoma, but the physiological and pathophysio-
logical relevance of this cross-talk remain to be clariﬁed (Sertznig
et al., 2009). Although the data available to date are insufﬁcient to
draw realistic conclusions, several studies suggest a protective role
of vitamin D in melanoma: Newton-Bishop et al. have recently
showed a signiﬁcant reduction in the risk of disease recurrence
in melanoma patients treated with vitamin D supplementation
compared with those not treated, the frequency of relapses was
reduced in particular with serum 25(OH)D >24 ng/ml (equiv-
alent to 60 nmol/l). In this study, higher 25(OH)D levels were
associated with lower Breslow thickness at diagnosis and were
independently protective of relapse and death (Newton-Bishop
et al., 2009). Nürnberg also showed an association between low
levels of circulating 25(OH)D and progression of melanoma,
with a substantially reduced levels of 25(OH)D in patients with
melanoma progression in stage IV than those in stage I. Further-
more, those patients with low 25(OH)D serum levels (<10 ng/ml)
developed earlier distant metastatic disease compared to those
with higher 25(OH) D serum levels (>20 ng/ml; Nürnberg et al.,
2009). A randomized placebo-controlled trial evaluated the effects
of vitamin D combined with calcium (CaD) supplementation
on skin cancer among postmenopausal women aged 50–79 years
(N = 36,282) enrolled into the Women’s Health Initiative (WHI):
vitamin D plus calcium (CaD) supplementation (1,000mg of ele-
mental calcium plus 400 IU of cholecalciferol daily) for a mean
follow-up period of 7.0 years did not reduce the overall incidence
of NMSC or melanoma, but in women with history of NMSC,
CaD supplementation reduced melanoma risk (Tang et al., 2011).
VITAMIN D AND COLORECTAL CANCER
Since 1980, when a protective role of vitamin D in colorectal
cancer was ﬁrstly suggested, many epidemiological studies have
been developed to conﬁrm this hypothesis. A crucial point was the
observation that mortality from colorectal cancer increased with
geographical latitude: the progressive decrease of levels of vitamin
D as results of weaker UV-B radiation seen at higher latitudes was
taken in account to explain the geographical patternof cancermor-
tality (Garland and Garland, 1980). It is now well established that
vitamin D and its metabolites act as inhibitors of colorectal cancer
progression via several underlying mechanisms, some of which
have been clariﬁed during past few years. Vitamin D inﬂuences
both the initiation and progression of colorectal cancer interact-
ing with Wnt/beta-catenin signaling (a recognized contributor to
colorectal cancer progression) and the innate immune response (;
Shah et al., 2006; Byers et al., 2012).
A recent meta-analysis of longitudinal epidemiological stud-
ies evaluated the relationship between Vitamin D levels and risk
of colorectal cancer: Eight studies comprising 3,556 patients were
included in the analysis and support previous evidence that serum
Vitamin D levels are inversely associated with risk of colorectal
cancer for patients with 25(OH)D levels in the highest compared
with lowest quintiles. An increase of 25(OH)D by 20 ng/ml was
associated with a risk reduction of 59% for rectal cancer and 22%
for colon cancer. Analyses stratiﬁed by anatomical site suggest a
stronger risk reduction for rectal cancers compared with colon
cancers, however, this ﬁnding did not reach statistical signiﬁcance
(Yin et al., 2009). One of the largest studies to date and one of the
ﬁrst based on European populations showed that compared with a
mid-range concentration of 50–75 nmol/l, 25(OH)D levels lower
than 25 ng/ml (50 nmol/l) were associated with an increased risk
of colorectal cancer (Jenab et al., 2010). Patients with 25(OH)D
levels greater than 100 nmol/l had a signiﬁcant 40% lower risk
of colorectal cancer than those patients with levels lower than
25 nmol/l. Previous studies have also shown that low levels of vit-
amin D are associated with increased mortality and aggressiveness
of colorectal cancer, while there was a signiﬁcant 30% reduction
in formation of colorectal adenomas among patients with higher
versus lower 25(OH)D levels. These studies, together with in vitro
studies demonstrating that colorectal epithelial cells express the
VDR, represent the start point to hypothesize a therapeutic effect
of Vitamin D in colorectal cancer and to design several therapeu-
tic studies. However, data are conﬂicting: the study of the WHI
(Women’s Health Initiative), conducted on 36,282 women in post
menopausal period for 7 years, showed no signiﬁcant protective
effect of supplementation with vitamin D (400 IU/day) on the
development of colorectal cancer. This study had some bias: (i) a
poor response to treatment among women enrolled (ii) the simul-
taneous intake of estrogen, which modify the effects of treatment
(iii) too low doses of vitamin D (400 IU/day) to correct the deﬁcit
and to ensure an antiproliferative effect (Wactawski-Wende et al.,
2006; Ding et al., 2008). A meta-analysis conducted subsequently
by Gorham et al. (2007), which divided 25(OH)D concentra-
tions into quintiles, showed a 50% reduction in the incidence
of colorectal cancer with serum levels of 25(OH)D >32 ng/ml
(Gorham et al., 2007). A recent and extensive European obser-
vational study conﬁrmed a strong inverse relationship between
25(OH)D concentrations and risk of developing colorectal can-
cer: among subjects with 25(OH)D levels equal to the highest
quintile the risk was reduced by 40% compared with subjects with
25(OH)D levels corresponding to the lowest quintile (Jenab et al.,
2010).
VITAMIN D AND ENDOCRINE TUMORS
The pathway of vitamin D seems to be involved in the develop-
ment of endocrine and neuroendocrine tumors too. The Pit-1
(pituitary transcription factor) is a transcription factor present in
pituitary and other cells and tissues, some studies highlighted its
complex relationship with the expression of VDR (Seoane et al.,
2007), this close relationship may represent a Key mechanism of
carcinogenesis in endocrine organs. Studies in cell cultures of
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medullary thyroid carcinoma showed contrasting effects of vit-
amin D: stimulatory on cell proliferation and inhibitory on the
secretion of calcitonin (Baier et al., 1994), but an antiprolifer-
ative effect of calcitriol has also been showed in the same cancer
histotype (Zabel et al., 2003). Regarding differentiated thyroid car-
cinoma cells, an over-expression of theVDR has been detected and
an antiproliferative effects of vitaminD (G1 phase arrest and accu-
mulation of p27) in a dose-dependent manner has been reported.
Khadzkou et al. evaluatedpapillary thyroid carcinoma (PTC) spec-
imens for VDR and 1-a-hydroxylase expression by RT-PCR and
immunohistochemistry. The majority of patients showed VDR
and 1-a-hydroxylase in areas of PTC, but negative staining in nor-
mal thyroid epithelium. VDR levels were signiﬁcantly lower in
PTC lymph node metastases than in primary tumors or matched
normal tissue, even if this study did not assess vitamin D lev-
els in patients to investigate the correlation with tumor histology
(Liu et al., 2002; Khadzkou et al., 2006). A recent study investi-
gated the effects of calcitriol on the development/progression of
capsular invasive carcinomas (CICs), using a rat thyroid carcino-
genesis model. It has been found that treatment with calcitriol
under sulfadimethoxine (SDM)-promotion for 13weeks reduced
the multiplicity of CICs, while cell proliferation activity, esti-
mated by the number of Ki-67-positive cells in CICs, did not
differ between the SDM-alone and SDM plus calcitriol groups;
the authors suggest that calcitriol targets cell proliferation inhibit-
ing phosphoinositide 3-kinase (PI3K)/Akt signaling, controlling
G1/S transition (Kemmochi et al., 2011).
Another study showed an additive and synergistic antiprolif-
erative effects of a combination treatments of 1,25(OH)2D or
its superagonistic analog CD578 in anaplastic thyroid cancer, in
combination with paclitaxel and suberoylanilide hydroxamic acid
(SAHA; Clinckspoor et al., 2011).
In murine and human insulinoma cell lines, the 1,25(OH)2D
demonstrated to inhibit cell proliferation, induce apoptosis, up-
regulate VDR expression, and promote non-genomic activation
of the MAPK pathway. Moreover, calcitriol signiﬁcantly decreased
insulin release and mRNA levels of human islets and insulinoma
cells. In insulinoma cell lines, the calbindin, a protein binding
calcium in a vitamin D dependent manner and expressed only
in neuroendocrine tumors, stimulate insulin secretion. Recom-
binant insulin/Simian virus 40 oncogene-expressing transgenic
mice treated with calcitriol showed reduced insulinoma volumes
through an increased apoptosis of adenomatous cells (Pochet
et al., 1989; Galbiati et al., 2002). In multiple endocrine neopla-
sia type 1 (MEN1), since menin can interact directly with the
VDR and enhance the transcriptional activity of VDR,menin deﬁ-
ciency explains the low levels of VDR gene expression detected
(Dreijerink et al., 2009).
In Table 2 the studies evaluating the association between
vitamin D metabolites and cancer in humans are summarized.
VITAMIN D AND CANCER PREVENTION
The potential use of vitamin D and its analogs in the prevention
and treatment of cancer raises a considerable scientiﬁc interest
(Chen and Kittaka, 2011; Reichrath et al., 2012). According to the
present paradigm,1,25(OH)2D (calcitriol) is biologically themost
active hormone, whereas 25(OH)D is considered as a biologically
Table 2 | Studies evaluating the association between vitamin D
metabolites and cancer in humans.
Reference Cancer Calcidiol Calcitriol
Ma et al. (1998) Prostate S S
Jacobs et al. (2011) Prostate NS NS
Barnett et al. (2010) Prostate S –
Ahn et al. (2009) Prostate S NS
Travis et al. (2009) Prostate NS –
Robsahm et al. (2004) Breast S –
Janowsky et al. (1999) Breast NS S
Garland et al. (2007) Breast S –
Abbas et al. (2008) Breast S –
Mohr et al. (2008) Breast S –
Newton-Bishop et al. (2009) Melanoma S –
Nürnberg et al. (2009) Melanoma S –
Robsahm et al. (2004) Colon S –
Yin et al. (2009) Colon S –
Jenab et al. (2010) Colon S –
Wactawski-Wende et al. (2006) Colon NS –
Gorham et al. (2007) Colon S –
S, statistically signiﬁcant; NS, not signiﬁcant; –, not studied.
inactive prohormone activated within the cell through the action
of 1a-hydroxylase (CYP27B1; Trump et al., 2004). The paradigm
presents the following discrepancies: serum calcidiol concentra-
tion is a clinically valid indicator of vitamin D availability and
action, whereas calcitriol concentration is not so clinically use-
ful in clinical practice if not in speciﬁc conditions (hepatic and
renal failure, hypoparathyroidism, malabsorption). The physio-
logical concentration of calcidiol is ∼1,000-fold greater than that
of calcitriol, but the in vitro studies usually compare the responses
at equal concentrations. The receptor appears to be mainly occu-
pied with calcidiol in vivo and if calcidiol would be inactive, no
vitamin D action could be detected. Lou et al. (2004) reported
the evidence that calcidiol could be an active hormone: it was
found to signiﬁcantly inhibit growth of the human prostatic stro-
mal cells at a high physiological concentration (250 nM), whereas
pharmacological (toxic) concentrations of calcitriol (10 nM) were
needed for the same effect. The vitamin D responsive gene, CYP24
(24-hydroxylase), was clearly induced by calcidiol at 250 nM and
by calcitriol at 10 nM. When using inhibitors of 24-hydroxylase,
VID-400, or of 1a-hydroxylase, SDZ88-357, the effect of calcidiol
was not inhibited but enhanced, suggesting calcidiol has inherent
hormonal activity (Lou et al., 2004). In a more recent study with
CYP27B1 mutated kidney cell line lacking 1a-hydroxylase activity,
a direct evidence for the hormonal activity of calcidiol in vitro has
been demonstrated. The use of the inhibitors of enzymes of vita-
minDmetabolism, conﬁrmed the hormonal activity of calcidiol in
several cell lines. Therefore, it canbe concluded that calcidiolmight
be the key hormone regulating differentiation and mitotic balance
andmight thus be involved in the development and/or progression
of chronic diseases and cancers. Calcitriol might be more involved
in the regulation of intracellular and extracellular calcium balance
through PTH (Tuohimaa, 2008). Therefore, in order to obtain a
correct evaluation of the organic reserves of this hormone and its
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potential cytostatic effect is necessary to refer to levels of 25(OH)D
(a longer half-life) other than levels of 1,25(OH)2 D. Signiﬁcantly
supraphysiological concentrations of calcitriol are required for
antineoplastic effects but optimal serum concentrations 25(OH)D
for cancer prevention have not been deﬁned. For all investi-
gated endpoints, the most advantageous serum concentrations of
25(OH)D begin at 75 nmol/l (30 ng/ml), and the best are between
90 and 110 nmol/l (36–44 ng/ml). Perhaps the most robust of the
epidemiologic studies is that of Giovannucci et al. (2006) who
developed and validated an estimate of serum 25(OH)D level and
reported that among more than 40,000 individuals an increase
in 25(OH)D level of 62.5 ng/ml was associated with a reduc-
tion in the risk of head/neck, esophagus, pancreas cancers, and
acute leukemia by >50%. Current intake recommendations may
be insufﬁcient for important disease outcomes such as cancer, and
several studies assessed the beneﬁt of higher-dose (above current
recommendations) and higher achieved 25-hydroxyvitaminD lev-
els [25(OH)D], although the MTD of calcitriol is unclear. Mean
levels of 75–110 nmol/l were reached inmost RandomizedControl
Trials with 1,800–4,000 IU vitamin D per day without increasing
health risk. As response to treatment varies by environmental fac-
tors and starting levels of 25(OH)D, testingmay bewarranted after
at least 3months of supplementation. The deﬁnition of vitamin D
deﬁciency is still controversial. Most agree that a 25(OH)D con-
centration <50 nmol/l, or 20 ng/ml, is an indication of vitamin
D deﬁciency, whereas a 25(OH)D concentration of 51–74 nmol/l,
or 21–29 ng/ml, is considered to indicate insufﬁciency; concentra-
tions>30 ng/ml are considered to be sufﬁcient (Beer andMyrthue,
2004; Bischoff-Ferrari et al., 2006; Holick and Chen, 2008).
SUMMARY AND PERSPECTIVES
Vitamin D metabolites exert signiﬁcant antineoplastic activity
in preclinical models. In clinical studies, an impact of vitamin
D has been reported in different types of cancer. A low vita-
min D activity is associated with an increased cancer risk and a
more aggressive tumor growth, while high activity of this pathway
induces antitumoral effects. In particular, serum circulating lev-
els of 25(OH)D levels <20 ng/ml seems to expose to the risk of
developing mammary and colorectal cancer.
Genomic and non-genomic mechanisms have been described
to explain the vitamin D-induced antineoplastic activity. Genomic
effects are mainly responsible for direct antiproliferative responses
to vitamin D,while non-genomic effects may contribute to inhibit
cell proliferation through the activation of second messengers
which are able to cross-talk with genomic effects.
The immune system seems to represent a relevant target for
the antineoplastic effects of vitamin D. In fact, VDR is expressed
in different types of inﬂammatory cells and vitamin D is able to
exert inhibitory effects on chronic inﬂammation and consequent
immune cell proliferation, which play a central role in promot-
ing the cancer development in colon, liver, stomach, prostate, and
many other cells and tissues.
Vitamin D activity and role has been especially investigated
for prostate, breast, colorectal, and skin cancer. The antiprolifera-
tive, pro-differentiating, and anti-metastatic effects of vitamin D
metabolites on prostate cells have been demonstrated in vitro but
are not always as obvious in vivo. In mammary gland, vitamin D
activity is known to contribute to the physiological development
of the gland, while low levels of circulating 25(OH)D were corre-
lated to the risk of developing breast cancer. In breast cancer cells,
CYP24A1, which promotes the degradation of 1,25(OH) 2D, is
increased, so suggesting that the malignant tissue has a tendency
to inactivate the vitamin D pathway.
It is now well established whether vitamin D and its metabo-
lites act as inhibitors of colorectal cancer progression. However,
it is likely that vitamin D inﬂuences both the initiation and pro-
gression of colorectal cancer interacting with Wnt/beta-catenin
signaling and the innate immune response.
To establish the relationship between vitamin D and risk of
melanoma is not easy and data available to date are insufﬁcient
to draw realistic conclusions. A protective role of vitamin D in
melanoma is suggested by the evidence that the 1,25(OH)2D reg-
ulates cell growth and apoptosis in human keratinocytes, exerts
antioxidative, cytoprotective, and immunomodulatory effects in
the skin, protects human keratinocytes against UV-B-induced cell
damage. A recent study showed that higher 25(OH)D levels were
associated with lower Breslow thickness at diagnosis and were
independently protective of relapse and death.
The pathway of vitamin D seems to be involved in the develop-
ment of endocrine and neuroendocrine tumors too, but few and
contrasting data are available to date. Some studies highlighted
the complex relationship between Pit-1 (pituitary transcription
factor), a transcription factor present in pituitary and other tis-
sues, and VDR. Regarding differentiated thyroid carcinoma cells,
an antiproliferative effects of vitaminD (G1 phase arrest and accu-
mulation of p27) in a dose-dependent manner has been reported.
In MEN1, VDR gene resulted to be scarcely expressed, probably
due to menin deﬁciency, characteristic of the syndrome.
Vitamin D may also plays a role in the genetic predisposition to
cancer development. The relationship between some tumor types
and speciﬁc SNPs of the VDR gene has been investigated. About
200 different SNPs of VDR have been described. The VDR SNPs
more frequently evaluated are Fok1, Bsm1, Taq1, Apa1, EcoRV,
Cdx2. The strongest relationship was found between BsmI, FokI
and melanoma, BsmI, FokI, ApaI and prostate cancer, BsmI, FokI,
TaqI and breast cancer. However, at now data are often contradic-
tory and it is still not possible to achieve any conclusion about the
correlation between VDR genotype and cancer occurrence.
Further studies are required to better clarify the molecular
mechanisms of the antineoplastic activity of vitamin D and site-
and tumor-speciﬁc expression and function of vitamin D path-
way. In our opinion, one of the most intriguing aspect to explore
in the next future is the role of vitamin D supplementation in
the general population or in populations susceptible to speciﬁc
types of tumors, in order to establish if it is protective against can-
cer development. It will be also interesting to explore therapeutic
applications of vitamin D and its analogs in patients with cancer.
In particular, better understanding of responsive phenotypes and
speciﬁc combination with cytotoxic drugs are promising tools for
the future use of vitamin D in cancer treatment.
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